KEYMED BIO-B(02162),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

02162 KEYMED BIO-B

Market Closed 09-04 16:08:03

79.750

-0.800

-0.99%

High82.400	Low79.300	Vol1.65M
Open81.350	D1 Closing80.550	Amplitude3.85%
Mkt Cap23.85B	Tradable Cap23.85B	Total Shares299.00M
T/O132.04M	T/O Rate0.55%	Tradable Shares299.00M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

Disclaimer: HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its absolute accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.

{"stockData":{"symbol":"02162","market":"HK","secType":"STK","nameCN":"KEYMED BIO-B","latestPrice":79.75,"timestamp":1788509283005,"preClose":80.55,"halted":0,"volume":1652339,"delay":0,"changeRate":-0.009931719428926098,"floatShares":299000000,"shares":299000000,"eps":-1.91,"marketStatus":"Market Closed","change":-0.8,"latestTime":"09-04 16:08:03","open":81.35,"high":82.4,"low":79.3,"amount":132036758,"amplitude":0.038485,"askPrice":79.75,"askSize":5500,"bidPrice":79.65,"bidSize":4500,"shortable":3,"etf":0,"ttmEps":3.044545,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1788744600000},"marketStatusCode":7,"adr":0,"listingDate":1625673600000,"exchange":"SEHK","adjPreClose":80.55,"openAndCloseTimeList":[[1788485400000,1788494400000],[1788498000000,1788508800000]],"volumeRatio":0.8622680951308471,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/02162","defaultTab":"news","newsList":[{"id":"1128255768","title":"HK Stock Alert: Keymed Bio Surges Over 3% on Landmark Licensing Deal with Aeira","url":"https://stock-news.laohu8.com/highlight/detail?id=1128255768","media":"Stock News","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1128255768?lang=en_us&edition=fundamental","pubTime":"2026-09-03 14:18","pubTimestamp":1788416295,"startTime":"0","endTime":"0","summary":"Shares of KEYMED BIO-B (02162) climbed more than 3% in Hong Kong trading, last up 2.83% at HK$79.95 with turnover reaching HK$70.71 million. The rally follows the company's announcement of an...","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1583","KCAI","BK1161","VXUS","BK1587","BK1574","BK4588","BK4585","02162"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664826668","title":"Keymed Biosciences Climbs on Licensing Deal with Aeira Pte","url":"https://stock-news.laohu8.com/highlight/detail?id=2664826668","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664826668?lang=en_us&edition=fundamental","pubTime":"2026-09-03 12:31","pubTimestamp":1788409914,"startTime":"0","endTime":"0","summary":"BUZZ-Keymed Biosciences climbs on licensing deal with Aeira Pte** Shares of Keymed Biosciences Inc2162.HKclimb 2.9% in the third straight rising session to HK$80, their highest level since August 27** Keymed says it entered into an exclusive licensing agreement with pharmaceutical firm Aeira Pte, on marketing registration and commercialization of Stapokibart injection - an antibody drug for treatment of topic dermatitis, in 18 countries and regions including Southeast and Central Asia** Keymed says it will receive an upfront payment, milestone payments and commercialization milestone payments and it is entitled to receive royalties of up to a high double-digit percentage based on product net sales in the licensed territory** YTD, stock up 46.7%, Hang Seng Biotech Index.HSBIOup 10.6%","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260903:nL1N44V04C:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02162","BK1583","BK1161","BK1587","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664582856","title":"Keymed Biosciences Signs Licensing Deal for Kangyueda in 18 Markets","url":"https://stock-news.laohu8.com/highlight/detail?id=2664582856","media":"MT Newswires","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664582856?lang=en_us&edition=fundamental","pubTime":"2026-09-03 09:42","pubTimestamp":1788399758,"startTime":"0","endTime":"0","summary":"Keymed Biosciences  has signed a licensing agreement with Singapore-based Aeira to market and sell Kangyueda in 18 markets across Central and Southeast Asia, according to a Wednesday bourse filing.Kangyueda is approved to treat moderate-to-severe atopic dermatitis in adults, chronic rhinosinusitis with nasal polyposis and seasonal allergic rhinitis, the filing said.Under the deal, Keymed will receive an upfront payment, milestone payments upon hitting certain targets and royalties in the high-double-digit percentage range based on regional sales.Aeira will be responsible for regulatory filings and the commercialization of Kangyueda in markets including Singapore, Malaysia, the Philippines, Thailand, Kazakhstan and Uzbekistan, as well as Hong Kong and Macau.Keymed will oversee the production and timely supply of Kangyueda to Aeira.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"b010cf239ffd4765bcd3edd8f767f746","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Keymed Biosciences Signs Licensing Deal for Kangyueda in 18 Markets","news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","02162","BK1587","BK1583","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664478814","title":"Keymed Biosciences Licenses Stapokibart Marketing, Sales Rights in 18 Southeast and Central Asia Markets to Aeira","url":"https://stock-news.laohu8.com/highlight/detail?id=2664478814","media":"Reuters","labels":["corporation","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664478814?lang=en_us&edition=fundamental","pubTime":"2026-09-02 21:04","pubTimestamp":1788354268,"startTime":"0","endTime":"0","summary":"Keymed Biosciences licenses Stapokibart marketing, sales rights in 18 Southeast and Central Asia markets to AeiraKeymed entered an exclusive licensing deal with Aeira to register and commercialize Sta","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260902:nNDL7LCJLF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","BK1583","02162","BK1574","BK1587"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664814417","title":"KeyMed Biosciences - Aeira Responsible for Registration and Commercialization of Stapokibart Injection in 18 Countries and Regions","url":"https://stock-news.laohu8.com/highlight/detail?id=2664814417","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664814417?lang=en_us&edition=fundamental","pubTime":"2026-09-02 21:04","pubTimestamp":1788354266,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260902:nFWN44T1AZ:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1161","BK1587","BK1583","BK1574","02162"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664144128","title":"KeyMed Biosciences - Enters Exclusive Licensing Agreement with Aeira Pte for Stapokibart Injection","url":"https://stock-news.laohu8.com/highlight/detail?id=2664144128","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664144128?lang=en_us&edition=fundamental","pubTime":"2026-09-02 21:04","pubTimestamp":1788354266,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260902:nFWN44T1AZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1583","BK1574","BK1587","02162","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1186220284","title":"KEYMED BIO-B: DFZQ Disposes of Shares, Long Position Falls to 4.98%","url":"https://stock-news.laohu8.com/highlight/detail?id=1186220284","media":"HK Disclosure","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1186220284?lang=en_us&edition=fundamental","pubTime":"2026-09-02 17:15","pubTimestamp":1788340505,"startTime":"0","endTime":"0","summary":"On August 27, 2026, DFZQ disposed of 48,000 shares of KEYMED BIO-B at an average of HKD 78.401 per share, involving about HKD 3.76 million.Prior to the disposal, DFZQ's long position in KEYMED BIO-B...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"a44b570a4bc942c79569e09a943adc8c","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02162"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1167342817","title":"Keymed Bio-B Reports No Share Capital Changes for August 2026, Confirms Adequate Public Float","url":"https://stock-news.laohu8.com/highlight/detail?id=1167342817","media":"Bulletin Express","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1167342817?lang=en_us&edition=fundamental","pubTime":"2026-09-02 17:03","pubTimestamp":1788339834,"startTime":"0","endTime":"0","summary":"Keymed Biosciences Inc. (Keymed Bio-B) filed its monthly return for the period ended 31 August 2026, indicating unchanged share capital metrics and continued compliance with Hong Kong’s public-float...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02162"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1141085303","title":"Fund Manager Trims Stake in KEYMED BIO-B With HK$3.76M Share Sale","url":"https://stock-news.laohu8.com/highlight/detail?id=1141085303","media":"Stock News","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1141085303?lang=en_us&edition=fundamental","pubTime":"2026-09-01 19:50","pubTimestamp":1788263416,"startTime":"0","endTime":"0","summary":"Hong Kong stock exchange filings reveal that on August 27, China Universal Asset Management Co., Ltd. reduced its holdings in KEYMED BIO-B (02162) by 48,000 shares.The shares were sold at an average...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EWH","BK1583","BK1161","02162","BK1587","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1158860436","title":"KEYMED BIO-B: 汇添富基金管理股份有限公司 Disposes, Long Position Falls to 4.98%","url":"https://stock-news.laohu8.com/highlight/detail?id=1158860436","media":"HK Disclosure","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1158860436?lang=en_us&edition=fundamental","pubTime":"2026-09-01 17:41","pubTimestamp":1788255672,"startTime":"0","endTime":"0","summary":"On August 27, 2026, 汇添富基金管理股份有限公司 sold 48,000 shares of KEYMED BIO-B at an average of HKD 78.401 per share, involving about HKD 3.76 million.Prior to the disposal, the declarant's long position in...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"a44b570a4bc942c79569e09a943adc8c","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02162"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1143799433","title":"Citi Raises Keymed Bio Target Price to HK$97.5, Keeps Buy/High Risk Call","url":"https://stock-news.laohu8.com/highlight/detail?id=1143799433","media":"Deep News","labels":["shareholding","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1143799433?lang=en_us&edition=fundamental","pubTime":"2026-08-23 12:50","pubTimestamp":1787460624,"startTime":"0","endTime":"0","summary":"Citi has released a research report stating that KEYMED BIO-B (02162) posted first-half 2026 revenue of RMB 617 million, up 24% year-on-year. Within that total, sales of stapokibart reached RMB 393...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0477156953.USD","LU1506573853.SGD","BK4534","IE00BSNM7G36.USD","LU0072461881.USD","TFNS","LU0310800965.SGD","LU2462157665.USD","LU0648001328.SGD","BK1587","LU2125154935.USD","FTXO","BK4585","LU1201861249.SGD","LU2236285917.USD","LU0162691827.USD","LU1244550577.SGD","LU0128525689.USD","EWH","LU0980610538.SGD","LU0203345920.USD","BK4559","LU0320765646.SGD","LU0203347892.USD","BK1161","LU1244550221.USD","BK1574","LU2125154778.USD","BK4207","LU0130102774.USD","LU1074936037.SGD","LU1244550494.USD","LU1366192091.USD","BK1583","LU0106831901.USD","LU1791807156.HKD","LU1267930227.SGD","BK4588","LU2360032135.SGD","LU2456880835.USD","LU0098860793.USD","02162","LU0314106906.USD","LU2417539215.USD","LU1668664300.SGD","C","LU0130517989.USD","LU1144417596.USD","BK4566","LU0052756011.USD","LU0170899867.USD","LU1162221912.USD","BK4504","IYF"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1174192289","title":"Daiwa Raises KEYMED BIO-B Price Target to HK$110, Reaffirming Buy Call","url":"https://stock-news.laohu8.com/highlight/detail?id=1174192289","media":"Deep News","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1174192289?lang=en_us&edition=fundamental","pubTime":"2026-08-23 12:40","pubTimestamp":1787460029,"startTime":"0","endTime":"0","summary":"Daiwa has released a research report stating that KEYMED BIO-B (02162) 2026 first-half results broadly aligned with its previous profit alert and the firm's estimates. Management has raised the 2026...","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02162","BK1583","BK1161","BK1587","BK1574","EWH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661215890","title":"Keymed Biosciences Inc. Just Missed Earnings - But Analysts Have Updated Their Models","url":"https://stock-news.laohu8.com/highlight/detail?id=2661215890","media":"Simply Wall St.","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661215890?lang=en_us&edition=fundamental","pubTime":"2026-08-22 07:01","pubTimestamp":1787353294,"startTime":"0","endTime":"0","summary":"Investors in Keymed Biosciences Inc. ( HKG:2162 ) had a good week, as its shares rose 2.8% to close at HK$80.30...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2162/keymed-biosciences-shares/news/keymed-biosciences-inc-just-missed-earnings-but-analysts-hav","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2162/keymed-biosciences-shares/news/keymed-biosciences-inc-just-missed-earnings-but-analysts-hav","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["RGLO","GXDW","DECU","JOYT","BK1161","02162","BK1587","VOTE","VGFPF","FEBU","PMDE","BK1574","BK1583"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1162184322","title":"Citi Raises Keymed Bio's Target Price to HK$97.5, Maintains Buy/High-Risk Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=1162184322","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1162184322?lang=en_us&edition=fundamental","pubTime":"2026-08-21 15:54","pubTimestamp":1787298869,"startTime":"0","endTime":"0","summary":"Citi has released a research report highlighting that KEYMED BIO-B (02162) posted first-half 2026 revenue of RMB617 million, marking a 24% year-over-year increase. Notably, sales of stapokibart...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["C","LU1244550494.USD","LU0203347892.USD","FTXO","LU1244550221.USD","BK4504","TFNS","IYF","LU0320765646.SGD","LU0052756011.USD","LU0314106906.USD","LU2236285917.USD","LU0106831901.USD","BK1583","BK1574","LU0072461881.USD","BK1161","BK4566","BK1587","LU0980610538.SGD","BK4585","LU1201861249.SGD","LU1506573853.SGD","LU0170899867.USD","LU0310800965.SGD","LU1366192091.USD","LU1074936037.SGD","LU1144417596.USD","LU0648001328.SGD","LU2417539215.USD","LU0130102774.USD","BK4559","IE00BSNM7G36.USD","LU0203345920.USD","LU0477156953.USD","02162","LU0098860793.USD","BK4588","BK4207","BK4534","LU0130517989.USD","LU1668664300.SGD","LU2125154778.USD","LU0128525689.USD","LU1791807156.HKD","LU2125154935.USD","LU2360032135.SGD","LU0162691827.USD","LU2456880835.USD","LU1267930227.SGD","LU2462157665.USD","LU1244550577.SGD","EWH","LU1162221912.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1188524801","title":"Movement Alert｜KEYMED BIO-B Rises 5.14% in Regular Trading, Proposed STAR Market Listing and H1 Profit Turnaround Continue to Drive Gains","url":"https://stock-news.laohu8.com/highlight/detail?id=1188524801","media":"Market Focus","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1188524801?lang=en_us&edition=fundamental","pubTime":"2026-08-21 10:36","pubTimestamp":1787279764,"startTime":"0","endTime":"0","summary":"On August 21, KEYMED BIO-B rose 5.14% in regular trading, trading at HK$81.8/share, with turnover of HK$67.91 million, extending gains from the prior session.The rally follows multiple catalysts...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"KEYMED BIO Gains on STAR Market Listing Plan and H1 Profit Turnaround","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02162"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661303292","title":"Keymed Biosciences (SEHK:2162) Stock Questions Whether New Profit Can Last","url":"https://stock-news.laohu8.com/highlight/detail?id=2661303292","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661303292?lang=en_us&edition=fundamental","pubTime":"2026-08-21 04:33","pubTimestamp":1787257986,"startTime":"0","endTime":"0","summary":"Keymed Biosciences stock has cooled in recent weeks, with the share price down about 10.6% over the past month even after moving into the black over the last year. Today's earnings story is all about profit, not hype. Basic earnings per share for the first half of 2026 came in at ¥4.29, flipping from losses in 2025, and trailing twelve month earnings now support a P/E of 25.4x.\nThe market is treating that P/E as a question mark. The key issue now is whether investors see this new...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2162/keymed-biosciences-shares/news/keymed-biosciences-sehk2162-stock-questions-whether-new-prof","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2162/keymed-biosciences-shares/news/keymed-biosciences-sehk2162-stock-questions-whether-new-prof","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["PMDE","BK1583","FEBU","RGLO","BK1161","DECU","VOTE","BK1587","JOYT","BK1574","VGFPF","GXDW","02162"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660427280","title":"KeyMed Biosciences Announces 2026 H1 Results and Business Updates","url":"https://stock-news.laohu8.com/highlight/detail?id=2660427280","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660427280?lang=en_us&edition=fundamental","pubTime":"2026-08-20 22:10","pubTimestamp":1787235014,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260820:nTUA5MDWKS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1583","BK1574","BK1161","BK1587","02162"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660232280","title":"Press Release: Keymed Biosciences Announces 2026 H1 Results and Business Updates","url":"https://stock-news.laohu8.com/highlight/detail?id=2660232280","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660232280?lang=en_us&edition=fundamental","pubTime":"2026-08-20 22:10","pubTimestamp":1787235000,"startTime":"0","endTime":"0","summary":"CHENGDU, China, Aug. 20, 2026 /PRNewswire/ -- On August 19, 2026, Keymed Biosciences (HKEX: 02162) announced its interim results for the six months ended June 30, 2026. Guided by a clear dual-engine d","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","02162","BK1574","BD","BK1583","BK4096","BK1587","PN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1198772075","title":"Historic Breakthrough in mRNA Cancer Vaccines: E Fund Biotech ETF (03186) Taps Innovation Opportunities Across Hong Kong and US Markets","url":"https://stock-news.laohu8.com/highlight/detail?id=1198772075","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1198772075?lang=en_us&edition=fundamental","pubTime":"2026-08-20 16:50","pubTimestamp":1787215857,"startTime":"0","endTime":"0","summary":"On August 19, Moderna and Merck announced that their personalized mRNA cancer vaccine combined with Keytruda met the interim analysis goals in a Phase 3 trial for melanoma. This marks the world's...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2488822045.USD","06990","BK1588","LU0196878994.USD","159646","BK1161","02162","BK1587","03186","159929","09688","BK1574","BK1583"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1136749730","title":"KEYMED BIO-B Surges Over 6% Pre-Market as H1 Drug Sales Climb 132%","url":"https://stock-news.laohu8.com/highlight/detail?id=1136749730","media":"Deep News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1136749730?lang=en_us&edition=fundamental","pubTime":"2026-08-20 11:50","pubTimestamp":1787197821,"startTime":"0","endTime":"0","summary":"Shares of KEYMED BIO-B (02162) climbed more than 7% during intraday trading, with the stock last up 6.42% at HK$82, on a turnover of HK$103 million.The company announced on August 19, 2026 that its...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02162","BK1583","BK1587","BK1574","BK1161"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"stockEarnings":[{"period":"1week","weight":0.0159},{"period":"1month","weight":0.0218},{"period":"3month","weight":0.3656},{"period":"6month","weight":0.5219},{"period":"1year","weight":0.1642},{"period":"ytd","weight":0.492}],"compareEarnings":[{"period":"1week","weight":0.0026},{"period":"1month","weight":-0.0102},{"period":"3month","weight":0.0276},{"period":"6month","weight":-0.0041},{"period":"1year","weight":0.0236},{"period":"ytd","weight":0.0008}],"compareStock":{"symbol":"HSI","name":"HSI"},"description":"KeyMed Biosciences Inc is a biotechnology company principally engaged in the in-house discovery and development of innovative biological therapies in the autoimmune and oncology therapeutic areas. The Company also focused on the research and development of pharmaceutical products. The Company's main products comprise CM310, CM326, CM313 and CM383, mainly used for treating various type II immunological diseases in adults, adolescents and children, including moderate-to-severe atopic dermatitis (AD), moderate-to-severe asthma, CRSwNP, AR and potentially COP. The Company has also established a fully integrated platform covering the key functions of biopharmaceutical development. The Company mainly conducts its businesses in the domestic market and overseas markets.","yearOnYearQuotes":[{"month":1,"riseRate":0.4,"avgChangeRate":-0.062159},{"month":2,"riseRate":0.6,"avgChangeRate":0.057033},{"month":3,"riseRate":0.4,"avgChangeRate":0.01927},{"month":4,"riseRate":1,"avgChangeRate":0.079263},{"month":5,"riseRate":0.2,"avgChangeRate":-0.114444},{"month":6,"riseRate":1,"avgChangeRate":0.128513},{"month":7,"riseRate":0.6,"avgChangeRate":0.112367},{"month":8,"riseRate":0.666667,"avgChangeRate":0.036143},{"month":9,"riseRate":0.833333,"avgChangeRate":0.046218},{"month":10,"riseRate":0.4,"avgChangeRate":0.003137},{"month":11,"riseRate":0.6,"avgChangeRate":0.04569},{"month":12,"riseRate":0.2,"avgChangeRate":-0.144855}],"exchange":"SEHK","name":"KEYMED BIO-B","nameEN":"KEYMED BIO-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.49.0","shortVersion":"4.49.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"KEYMED BIO-B(02162),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest KEYMED BIO-B(02162) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"KEYMED BIO-B,02162,KEYMED BIO-B股票,KEYMED BIO-B股票老虎,KEYMED BIO-B股票老虎国际,KEYMED BIO-B行情,KEYMED BIO-B股票行情,KEYMED BIO-B股价,KEYMED BIO-B股市,KEYMED BIO-B股票价格,KEYMED BIO-B股票交易,KEYMED BIO-B股票购买,KEYMED BIO-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"KEYMED BIO-B(02162),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest KEYMED BIO-B(02162) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}